Answers are grounded in this paper and cite their sources.
Chemoimmunotherapy resistance significantly limits the clinical management of esophageal squamous cell carcinoma (ESCC). To identify tumor-intrinsic regulators associated with an immunosuppressive tumor microenvironment (TME) and treatment failure, we integrated proteomic profiling of clinical ESCC specimens (n=8) and single-cell RNA sequencing of three ESCC tumors and one normal control, identifying CYP2S1 as upregulated in chemoimmunotherapy-resistant tumors and predominantly expressed by malignant epithelial cells. Immunohistochemical and multiplex immunofluorescence analyses further showed that CYP2S1-high tumors contained increased numbers of phenotypically defined polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) cells. Consistent with a potential relationship between CYP2S1 expression and poor treatment response, the CYP2S1 immunohistochemical score was positively associated with Mandard tumor regression grade in 46 evaluable patients (linear regression R 2 = 0.271, P = 0.0002; Spearman ρ = 0.528, P < 0.001). Mechanistically, CYP2S1 knockdown reduced intracellular reactive oxygen species (ROS) levels and the expression of several myeloid-attracting chemokines, whereas CYP2S1 overexpression increased ROS and most consistently induced CXCL6 and CXCL8. In ROS-scavenging experiment, treatment with N-acetylcysteine attenuated CYP2S1 overexpression-associated ROS accumulation, reduced CXCL6 and CXCL8 mRNA induction, and decreased CXCL8 secretion, supporting a ROS-dependent component of this chemokine program. Collectively, these findings associate tumor cell CYP2S1 with a ROS-linked CXCL6/CXCL8 signaling axis, PMN-MDSC-like accumulation, and unfavorable chemoimmunotherapy response in ESCC.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: